



OTI One-Pager (Investor Summary)

Company: Ophthalmic Therapeutic Innovation (OTI)

Sector: Biotech / Ophthalmology

Lead Asset: OTI-2024 — First-in-class adenosine small molecule for glaucoma, targeting tissue rejuvenation via MMP pathway.

Development Stage: Pre-Phase 3, IND submitted

Intellectual Property: Robust, mature IP portfolio protecting drug use in glaucoma via eye drops/sustained release formulation in general.

Market Opportunity: Multi-billion-dollar glaucoma therapeutics market with no current curative treatment

Why Invest in OTI?

- **Rare late-stage biotech opportunity:** Most startups offer ideas or prototypes; OTI owns a patented, clinically validated asset at pre-Phase 3 stage, IND-filed pending for reformulation (simple standard eye drops for small molecule -low risks).
- **De-risked asset:** Completed drug discovery, development, and IND submission—major regulatory hurdles cleared.
- **Clear use of funds:** Seeking \$100K minimum to cover critical IP/legal fees and stipend bridge funding toward \$3.0 M next milestone- eye drop reformulation prepared for Phase 3 pivotal trials.
- **Founder-led with proven commitment:** CEO with 3+ years bootstrapping, deep domain expertise in ophthalmology and stem cell biology
- **Path to exit:** Preparing for reformulation of \$3-4M to enable Phase 3 trials, or strategic licensing/sale to pharma (intangible assets: IP+IND).

- 👉 Invest or learn more: <https://wefunder.com/ophthalmictherapeuticinnovationllc>
- 📎 Company site: <http://ophthalmic-innovation.com>
- Reference: <https://pubmed.ncbi.nlm.nih.gov/33405971/>.

Disclaimers:

We are "testing the waters" to gauge investor interest in an offering under Regulation Crowdfunding. No money or other consideration is being solicited. If sent, it will not be accepted. No offer to buy securities will be accepted. No part of the purchase price will be received until a Form C is filed and only through Wefunder's platform. Any indication of interest involves no obligation or commitment of any kind.